Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023374 · ClinicalTrials.gov registry record · NA
TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
A NA study of Tuberculosis, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT00023374: Completed NA study of Tuberculosis, sponsored by Centers for Disease Control and Prevention.
NCT00023374 is a NA study of Tuberculosis that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 98 participants, below the 931-participant average among 29 other Tuberculosis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023374, a NA study of Tuberculosis, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a prospective, open-label, nonrandomized trial using a largely-intermittent, six-month tuberculosis treatment regimen among patients who will not receive isoniazid due to the presence of initial isoniazid resistance or intolerance. Subjects are enrolled after resistance or intolerance to isoniazid has been documented, and are treated for a total of six months (nine months if baseline chest x-ray shows cavitation and 2-month sputum culture is positive) with twice weekly or thrice weekly rifampin, ethambutol, and pyrazinamide.
Conditions Studied
Interventions
- DRUG Ethambutol
- DRUG Rifampin
- DRUG Pyrazinamide
- DRUG REZ
Study Locations (20)
New York
- New York University School of Medicine - New York
- Columbia University/Presbyterian Medical Center - New York
- Harlem Hospital Center - New York
Texas
- University of North Texas Health Science Center - Fort Worth
- Thomas Street Clinic - Houston
- Audi L. Murphy VA Hospital - San Antonio
California
- LA County/USC Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
Illinois
- Chicago VA Medical Center (Lakeside) - Chicago
- Hines VA Medical Center - Hines
North Carolina
- Carolinas Medical Center - Charlotte
- Duke University Medical Center - Durham
Arkansas
- Central Arkansas Veterans Health System - Little Rock
Colorado
- Denver Department of Public Health and Hospitals - Denver
District of Columbia
- Washington, D.C. VAMC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2000-08 |
| Est. Completion | 2010-12 |
| Phase | NA |
What the finished NCT00023374 record still lists
NCT00023374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 931-participant average among 29 other Tuberculosis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 4 interventions - of which Ethambutol is the first listed.
NCT00023374 names 20 study sites across 13 states, led by New York, Texas, California.
Frequently Asked Questions
What is clinical trial NCT00023374 about?
NCT00023374 is a clinical study titled "TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance". This study is a prospective, open-label, nonrandomized trial using a largely-intermittent, six-month tuberculosis treatment regimen among patients who will not receive isoniazid due to the presence of initial isoniazid resistance or intolerance. Subjects are enrolled after resistance or intolerance ...
What is the current status of trial NCT00023374?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2000-08. Estimated completion is 2010-12.
What conditions does trial NCT00023374 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT00023374?
The interventions under investigation include: Ethambutol (DRUG), Rifampin (DRUG), Pyrazinamide (DRUG), REZ (DRUG).
Who is sponsoring clinical trial NCT00023374?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00023374 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00023374's enrollment target sits among peer trials
98 17th of 29 higher than 13 of 29 other Tuberculosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tuberculosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
COMPLETED · NA
-
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
COMPLETED · NA
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia